Show simple item record

dc.creatorBacković, Dragana
dc.creatorIgnjatović, Svetlana
dc.creatorRakicević, Ljiljana
dc.creatorKusić-Tisma, Jelena
dc.creatorRadojković, Dragica
dc.creatorČalija, Branko
dc.creatorStrugarević, Evgenija
dc.creatorRadak, Đorđe
dc.creatorKovac, Mirjana
dc.date.accessioned2019-09-02T11:51:35Z
dc.date.available2019-09-02T11:51:35Z
dc.date.issued2016
dc.identifier.issn1452-8258
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/2573
dc.description.abstractBackground: Despite the proven clinical effect of oral antiplatelet drugs, a considerable number of patients do not have an adequate response to clopidogrel. The aim of our study was to determine the influence of CYP2C19*2 loss-of-function variant allele on clopidogrel responsiveness in patients with carotid artery stenosis. Methods: One hundred and twelve patients with carotid artery stenosis undergoing endarterectomy were included in this one-year prospective study. All of them received clopidogrel (75 mg daily) for at least 30 days after the intervention. They were followed from the moment of hospital admission. CYP2C19*2 genotyping was performed by TaqMan Assay. The influence of CYP2C19*2 variant allele on clopidogrel platelet reactivity was determined using multiple-electrode aggregometry (MEA). Results: Genotyping results showed that 82 (73.2%) patients were homozygous for wild type, 29 (25.9%) were heterozygous for the CYP2C19*2 allele and 1 (0.9%) was CYP2C19*2 homozygous. After 24 hours, among those with the wild type 29.3% were clopidogrel responders, and in those with the CYP2C19*2 alleles 10%. In the wild type group, 74.4% were clopidogrel responders after 7 days of taking the drug; 82.9% after 30 days of clopidogrel introduction, respectively. In patients with the CYP2C19*2 alleles the number of responders increased up to 46.7% after 7 days; 53.3% after 30 days of taking the drug, respectively. The risk for being a low-responder is higher for the patients heterozygous for the CYP2C19*2 allele vs. wild type (OR 4.250, 95% CI 1.695-10.658, P lt 0.01). Conclusions: The CYP2C19*2 loss-of-function variant allele has significant influence on clopidogrel response in patients with carotid artery stenosis undergoing endarterectomy.en
dc.publisherDruštvo medicinskih biohemičara Srbije, Beograd i Versita
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173008/RS//
dc.rightsopenAccess
dc.sourceJournal of Medical Biochemistry
dc.titleInfluence of Cyp2c19∗2 Gene Variant on Therapeutic Response during Clopidogrel Treatment in Patients with Carotid Artery Stenosisen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractСтругаревић, Евгенија; Ракицевић, Љиљана; Кусић-Тисма, Јелена; Радојковић, Драгица; Радак, Ђорђе; Бацковић, Драгана; Ковац, Мирјана; Игњатовић, Светлана; Чалија, Бранко;
dc.citation.volume35
dc.citation.issue1
dc.citation.spage26
dc.citation.epage33
dc.citation.other35(1): 26-33
dc.citation.rankM23
dc.identifier.wos000371751500004
dc.identifier.doi10.1515/jomb-2015-0009
dc.identifier.pmid28356861
dc.identifier.scopus2-s2.0-84961360668
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs//bitstream/id/1249/2571.pdf
dc.identifier.rcubconv_3510
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record